Selected article for: "cigarette smoking and inflammatory response"
Author: Lugnier, Claire; AL-Kuraishi, Hayder M.; Rousseau, Eric
Title: PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking
  • Cord-id: wh3m0nfi
  • Document date: 2021_1_28
    • ID: wh3m0nfi
    Snippet: Angiotensin-converting enzyme 2 (ACE2) is the binding-site and entry-point for SARS-CoV-2 in human and highly expressed in the lung. Cigarette smoking (CS) is the leading cause of pulmonary and cardiovascular diseases. Chronic CS leads to upregulation of bronchial ACE2 inducing a high vulnerability in COVID-19 smoker patients. Interestingly, CS-induced dysregulation of pulmonary renin-angiotensin system (RAS) in part contributing into the potential pathogenesis COVID-19 pneumonia and acute respi
    Document: Angiotensin-converting enzyme 2 (ACE2) is the binding-site and entry-point for SARS-CoV-2 in human and highly expressed in the lung. Cigarette smoking (CS) is the leading cause of pulmonary and cardiovascular diseases. Chronic CS leads to upregulation of bronchial ACE2 inducing a high vulnerability in COVID-19 smoker patients. Interestingly, CS-induced dysregulation of pulmonary renin-angiotensin system (RAS) in part contributing into the potential pathogenesis COVID-19 pneumonia and acute respiratory distress syndrome (ARDS). Since, CS-mediated ACE2 activations is not the main pathway for increasing the risk of COVID-19, it appeared that AngII/AT1R might induce an inflammatory-burst in COVID-19 response by up-regulating cyclic nucleotide phosphodiesterase type 4 (PDE4), which hydrolyses specifically the second intracellular messenger 3’, 5’-cyclic AMP (cAMP). It must be pointed out that CS might induce PDE4 up-regulation similarly to the COVID-19 inflammation, and therefore could potentiate COVID-19 inflammation opening the potential therapeutic effects of PDE4 inhibitor in both COVID-19-inflammation and CS.

    Search related documents:
    Co phrase search for related documents
    • abnormal function and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • abnormal function and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
    • abnormal function and lung failure: 1, 2, 3
    • abnormal function and lung injury: 1, 2
    • abnormal function and lung macrophage: 1, 2
    • abnormal function and lung parenchyma: 1, 2
    • abnormal function and lung tissue: 1
    • ace activity and activity expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • ace activity and activity increase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • ace activity and acute ali lung injury: 1, 2
    • ace activity and acute ali lung injury ards: 1
    • ace activity and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • ace activity and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • ace activity and lung failure: 1, 2, 3
    • ace activity and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • ace activity and lung major role: 1
    • ace activity and lung tissue: 1, 2, 3, 4